Properties
What is it?
International Nonproprietary Name - cefuroxime Clinical-pharmacological group: Antibacterial agents → Beta-lactam antibiotics (penicillins and cephalosporins) → Cephalosporins → Second-generation cephalosporins Composition: Megacef 750 mg for IM/IV injection contains anhydrous cefuroxime sodium, equivalent to 750 mg cefuroxime and 42 mg (1.8 mmol) sodium. After reconstitution, the content of a 750 mg vial yields 0.53 ml. Indications and Usage Injectable Megacef is indicated for the treatment of the following infections caused by susceptible strains of microorganisms: Lower respiratory tract infections: including acute and chronic bronchitis, infected bronchiectasis, pneumonia, lung abscess, and postoperative pulmonary infections caused by the following strains: Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes, and Escherichia coli. Urinary tract infections: including acute and chronic pyelonephritis, cystitis, and asymptomatic bacteriuria caused by Escherichia coli and Klebsiella spp. Skin and skin structure infections: including cellulitis, erysipelas, and wound infections caused by Staphylococcus aureus (including penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes, Escherichia coli, Klebsiella spp., and Enterobacter spp. Septicemia: caused by the following strains: Staphylococcus aureus (including penicillinase- and non-penicillinase-producing strains), Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp. Meningitis: caused by the following strains: Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis, and Staphylococcus aureus (including penicillinase- and non-penicillinase-producing strains). Gonorrhea: especially in cases where penicillin is inadequate. Uncomplicated and disseminated gonococcal infections caused by Neisseria gonorrhoeae (including penicillinase- and non-penicillinase-producing strains). Dosage and Administration Unless otherwise prescribed by a physician, the following dosage regimen should be used: Adults: The dose in adults ranges from 750 mg to 1.5 g every 8 hours, usually for 5-10 days. For uncomplicated urinary tract infections, skin and skin structure infections, disseminated gonococcal infections, and uncomplicated pneumonia, a dose of 750 mg every 8 hours is recommended. For acute and complicated infections, the recommended dose is 1.5 g every 8 hours. For bone and joint infections, the recommended dose is 1.5 g every 8 hours. For life-threatening infections and infections caused by less susceptible organisms, 1.5 g should be administered every 6 hours. For bacterial meningitis, the dose should not exceed 3 g every 8 hours. The recommended dose for uncomplicated gonococcal infection is 1.5 g administered intramuscularly as a single dose in 2 different sites along with 1 g probenecid. For prophylaxis during surgical operations, 1.5 g is administered intravenously before the start of surgery (approximately half to one hour before the first incision). Subsequently, 750 mg is administered intravenously or intramuscularly every 8 hours in case of prolonged surgery. For prophylaxis during open-heart surgery, 1.5 g is administered intravenously during induction of anesthesia and then every 12 hours. The total dose administered should not exceed 6 grams.